[Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].
作者信息
Alten R, Mischkewitz M, Nitschmann S
机构信息
Abteilung Innere Medizin II - Rheumatologie, Klinische Immunologie, Osteologie, Physikalische Therapie und Sportmedizin, Schlosspark-Klinik, Heubnerweg 2, 14059, Berlin, Deutschland.
, Lippetal, Deutschland.
出版信息
Internist (Berl). 2020 May;61(5):530-532. doi: 10.1007/s00108-020-00766-4.
PMID:32130437
Abstract
摘要
相似文献
1
[Febuxostat or allopurinol in patients with gout : Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES)].痛风患者使用非布司他或别嘌醇：痛风合并心血管疾病患者中，非布司他和别嘌醇的心血管安全性（CARES研究）
Internist (Berl). 2020 May;61(5):530-532. doi: 10.1007/s00108-020-00766-4.
2
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.别嘌醇或非布司他治疗痛风患者的心血管安全性。
N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12.
3
Gout lessons from 2018: CARES, a direct comparison of febuxostat vs allopurinol, and CANTOS, IL1 blocker for cardiovascular risk minimisation.2018 年痛风治疗的经验教训：CARES 研究，非布司他与别嘌醇的直接比较；CANTOS 研究，IL-1 阻滞剂降低心血管风险。
Clin Rheumatol. 2019 Jan;38(1):263-265. doi: 10.1007/s10067-018-4396-4. Epub 2018 Dec 12.
4
Cardiovascular safety of febuxostat and allopurinol in patients with gout and cardiovascular comorbidities.别嘌醇和非布司他在伴有心血管合并症的痛风患者中的心血管安全性。
Am Heart J. 2012 Jul;164(1):14-20. doi: 10.1016/j.ahj.2012.04.011. Epub 2012 Jun 13.
5
The efficacy of febuxostat and allopurinol in the treatment of gout with hyperuricemia.非布司他与别嘌醇治疗痛风伴高尿酸血症的疗效。
Pak J Pharm Sci. 2018 Jul;31(4(Special)):1623-1627.
6
The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.非布司他对比别嘌醇用于痛风或无症状高尿酸血症患者的净临床获益：一项系统评价和荟萃分析。
Nutr Metab Cardiovasc Dis. 2019 Oct;29(10):1011-1022. doi: 10.1016/j.numecd.2019.06.016. Epub 2019 Jun 24.
7
New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.风湿学新视角：痛风伴心血管疾病患者中非布司他和别嘌醇心血管安全性的意义——New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial 和相关的美国食品药品监督管理局公共安全警示。
Arthritis Rheumatol. 2018 Nov;70(11):1702-1709. doi: 10.1002/art.40583.
8
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia.非布司他与别嘌醇简化试验（FAST）方案：一项大型前瞻性、随机、开放、盲终点研究，比较别嘌醇和非布司他在治疗症状性高尿酸血症中的心血管安全性。
BMJ Open. 2014 Jul 10;4(7):e005354. doi: 10.1136/bmjopen-2014-005354.
9
A word of caution regarding Febuxostat.关于非布司他的一则警示。
J Pak Med Assoc. 2019 Dec;69(12):1930. doi: 10.5455/JPMA.42025.
10
Diabetes and gout: efficacy and safety of febuxostat and allopurinol.糖尿病与痛风：非布司他与别嘌醇的疗效和安全性。
Diabetes Obes Metab. 2013 Nov;15(11):1049-55. doi: 10.1111/dom.12135. Epub 2013 Jun 12.
引用本文的文献
1
Unleashing the potential of exercise: conquering cardiovascular disease by targeting inflammasome activation.释放运动的潜力：通过靶向炎性小体激活来战胜心血管疾病。
Eur J Med Res. 2025 Jul 26;30(1):677. doi: 10.1186/s40001-025-02927-3.
2
NLRP3 inflammasome and pyroptosis in cardiovascular diseases and exercise intervention.NLRP3炎性小体与细胞焦亡在心血管疾病及运动干预中的作用
Front Pharmacol. 2024 Apr 12;15:1368835. doi: 10.3389/fphar.2024.1368835. eCollection 2024.
Zotero 插件